Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | 11.85 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.25 | 2.10 | 3.57 | 6.32 | 7.16 | 1.30 | 1.50 | 2.22 | — | 8.17 | 2.86 | 3.04 | — |
| — | +61.3% | +137.6% | +184.9% | — | -84.1% | -47.3% | -27.1% | — | +325.4% | +126.8% | +107.9% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 22.28 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | -622.5% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | -2159.3% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2028.1% | -22.3% | -46.5% | 6.1% | -122.0% | -13.8% | 37.1% | -233.9% | — | -84.4% | -44.2% | -290.0% | -256.2% |
| — | -61.1% | -225.3% | +102.6% | — | +83.6% | +183.9% | +19.3% | — | -10.4% | -40.9% | -1118.8% | -1551.3% | |
| ROA | -160.2% | -14.9% | -22.3% | 1.9% | -61.3% | -9.8% | 20.3% | -63.0% | -46.4% | -20.5% | -15.3% | -97.1% | -82.0% |
| — | -51.6% | -209.6% | +103.0% | -32.2% | +52.0% | +232.5% | +35.1% | +43.5% | +57.6% | +39.8% | -373.6% | -474.0% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 6.1% YoY to 3.83x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.01 | 0.03 | 0.06 | 0.10 | 0.03 | 0.02 | 0.03 | — | 0.25 | 0.14 | 0.09 | — |
| — | -75.6% | +43.2% | +87.1% | — | -88.5% | -85.3% | -65.1% | — | +501.3% | +385.6% | +321.6% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.28 | 3.83 | 2.18 | 1.64 | 1.28 | 3.61 | 3.37 | 1.71 | 0.76 | 1.20 | 1.42 | 1.64 | 0.81 |
| — | +6.1% | -35.3% | -3.9% | +67.9% | +200.4% | +136.7% | +4.1% | -5.1% | -33.4% | -67.9% | -74.5% | -90.8% | |
| Quick Ratio | 1.28 | 3.83 | 2.18 | 1.64 | 1.28 | 3.61 | 3.37 | 1.71 | 0.76 | 1.20 | 1.42 | 1.64 | 0.81 |
| — | +6.1% | -35.3% | -3.9% | +67.9% | +200.4% | +136.7% | +4.1% | -5.1% | -33.4% | -67.9% | -74.5% | -90.8% | |
| Interest Coverage | -452.35 | -489.47 | -535.62 | -532.60 | -463.05 | -416.73 | -462.56 | -460.20 | -332.26 | -329.89 | -135.06 | -350.17 | -1775.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonUnicycive Therapeutics, Inc.'s current P/E is -1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Unicycive Therapeutics, Inc.'s business trajectory between earnings reports.